01—Abstract
Summary
Summary of the 10-Q filed July 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. reported robust revenue growth for the nine months ended June 30, 2024, driven by a significant increase in its U.S. Healthcare Solutions segment.
This growth was fueled by higher unit volumes, particularly in GLP-1 class drugs for diabetes and weight loss, alongside increased sales of specialty products and COVID-19 vaccines. While gross profit saw a healthy increase, profit margins in the U.S. segment slightly contracted due to a higher mix of lower-margin GLP-1 products, though this was partially offset by higher-margin COVID-19 vaccine sales. The company's operating expenses also increased, impacted by higher distribution, selling, and administrative costs, as well as litigation and opioid-related expenses.
Despite these pressures, overall segment operating income showed positive growth, particularly in the U.S. segment. Cencora also highlighted strong cash flow from operations, which was bolstered by effective working capital management, particularly an extended accounts payable cycle. The company continued its share repurchase program and maintained its quarterly dividend.
Key financial considerations for investors include the ongoing strength in revenue, the impact of the GLP-1 drug trend on margins, and the significant ongoing liability related to opioid litigation, which continues to be managed with substantial reserves. The company's liquidity remains strong with significant availability under its credit facilities.
02—Key points
Key Highlights
- Revenue increased by 11.2% to $214.9 billion for the nine months ended June 30, 2024, primarily driven by the U.S. Healthcare Solutions segment's 12.1% growth.
- Gross profit for the nine months ended June 30, 2024, increased by 10.6% to $7.4 billion, reflecting increased sales across both segments.
- Operating income for the nine months ended June 30, 2024, grew by 9.9% to $2.0 billion, with the U.S. Healthcare Solutions segment showing a 13.9% increase.
- Net income attributable to Cencora, Inc. for the nine months ended June 30, 2024, was $1.5 billion, an increase from $1.4 billion in the prior year period.
- The company generated $2.48 billion in net cash provided by operating activities for the nine months ended June 30, 2024, an increase from $2.08 billion in the prior year.
- Cencora has an ongoing share repurchase program with $1.82 billion remaining availability as of June 30, 2024, and declared a quarterly dividend of $0.51 per share.
- The company's accrued litigation liability related to opioid litigation was $5.1 billion as of June 30, 2024, with estimated payments over the next 14 years.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Cencora, Inc. kept $0.01.
- Revenue$74.24B100.0%
- Cost of revenue−$71.83B96.8%
- Gross profit$2.41B3.2%
- Operating costs−$1.74B2.3%
- Operating income$672.5M0.9%
- Interest, other & tax−$189.0M0.3%
- Net income$483.5M0.7%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed July 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $74.24B$66.95B | +10.9% |
| Cost of Revenue | $71.83B$64.68B | +11.1% |
| Gross Profit | $2.41B$2.26B | +6.5% |
| SG&A Expenses | $1.38B$1.30B | +6.1% |
| Operating Income | $672.48M$670.13M | +0.4% |
| Net Income | $483.46M$479.58M | +0.8% |
| EPS (Basic) | $2.44$2.37 | +3.0% |
| EPS (Diluted) | $2.42$2.35 | +3.0% |
| Shares Outstanding (Basic) | 198.26M202.35M | −2.0% |
| Shares Outstanding (Diluted) | 200.05M204.38M | −2.1% |
05—Questions
Frequently Asked Questions
What were the main drivers of Cencora's revenue growth in the reported period?
Revenue growth was primarily driven by the U.S. Healthcare Solutions segment, which saw an increase of 12.1% for the nine months ended June 30, 2024. This growth was fueled by higher unit volumes, including increased sales of GLP-1 class drugs for diabetes and weight loss, specialty products to physician practices and health systems, and COVID-19 vaccines.
How is the company managing its significant opioid litigation liability?
Cencora has accrued a liability of $5.1 billion as of June 30, 2024, for opioid litigation, primarily related to the Distributor Settlement Agreement. Payments are expected to be made over the next 14 years. The company continues to litigate and defend itself in matters not covered by settlements and regularly reviews its accrual for adequacy.
What is the outlook for Cencora's profit margins, particularly concerning GLP-1 drugs?
While overall revenue is growing, gross profit margins in the U.S. Healthcare Solutions segment experienced a slight contraction (6 basis points for the quarter and 4 basis points for the nine months) primarily due to higher sales of GLP-1 products, which have lower gross profit margins. This was partially offset by higher-margin COVID-19 vaccine sales.
How is Cencora's liquidity and capital position?
The company maintained strong liquidity, with $3.3 billion in cash and cash equivalents as of June 30, 2024. Net cash provided by operating activities increased to $2.48 billion for the nine months ended June 30, 2024. Cencora also has significant availability under its credit facilities, totaling $3.93 billion in additional availability across various variable-rate debt facilities.
06—Continue